I Przychodnia Lekarska Komed Roman Karaszewski II Osrodek Badan Klinicznych III

The site is conducting research in ER‑Positive HER2‑Negative Breast Cancer, evaluating a new oral selective estrogen degrader combined with a CDK4/6 inhibitor to improve treatment outcomes for patients with advanced disease.

• Optimization of endocrine therapy strategies
• Integration of CDK4/6 inhibition
• Comparative effectiveness versus standard hormonal regimens

This work aims to extend progression‑free survival and provide a clearer therapeutic option for patients who have not yet received systemic treatment. The research is carried out at I Przychodnia Lekarska Komed Roman Karaszewski II Osrodek Badan Klinicznych III in Konin, Poland.

Clinical investigation at the centre focuses on HPV‑Positive Head and Neck Cancer, testing a novel therapeutic vaccine together with an immune checkpoint inhibitor to enhance anti‑tumor immunity.

• Evaluation of vaccine‑based immunotherapy
• Combination with PD‑L1 blockade
• Assessment of survival benefits

The trial seeks to improve both overall survival and progression‑free survival for patients with unresectable or recurrent disease, reflecting the site’s commitment to advancing treatments for neoplastic conditions. The research is conducted at the same Konin‑based clinical research facility.